BioCentury
ARTICLE | Company News

Imprimis, Buderer Drug deal

June 24, 2013 7:00 AM UTC

Imprimis acquired rights to undisclosed IP from compounding pharmacy Buderer and received a right of first refusal for additional IP. Imprimis said the undisclosed IP could lead to up to three develop...